Curie.Bio’s Post

According to Deloitte, developing a new drug costs about $2.3 billion. This hefty price tag is often accompanied by high hopes, but not all clinical trials are successful. Fierce Biotech has compiled a list of the top 10 clinical trial flops in 2023. Check out the article for an insightful read on the challenges of drug development. https://lnkd.in/eRjy65P6

Will you be at the #DrugDeliverySummit? 💊 DM Dan Dobry or David Vodak if you'd like to set up some time to meet. 💡 Let's talk about the next innovation in drug development. #PharmaCDMO #ContractManufacturing #DrugDevelopment #CDMOsolutions #InnovativeTherapeutics #AIinPharma Bend Bioscience + CoreRx, Inc.

Thoughts on this? >> Neurosterix emerges with $63M to follow Karuna, Cerevel >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #healthcare #pharma #biotech #pharmaceutical

Geez, using the term "flop" seems kind of harsh, but I get it. ;) At least the author added this: You can learn as much about how to develop a drug from past failures as you can from success. When you look at the biopharma pipeline, there are plenty of lessons learned to choose from. #clinicaltrials #clinicalresearch #medicalcommunications #medcomms #biotech https://lnkd.in/eDaaFYnm

Thoughts on this? >> Neurosterix emerges with $63M to follow Karuna, Cerevel >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #healthcare #pharma #pharmaceutical #productmarketing

Antibiotics are used to treat BV and UTI, but recurrences are common. Antibiotics inhibit or kill the bacteria that cause these conditions, but and they do not prevent recurrence since they do not restore protective Lactobacillus. To address this unmet medical need, Osel developed a proprietary Live Biotherapeutic Product (LBP), called LACTIN-V that contains the protective vaginal strain, Lactobacillus crispatus CTV-05. L. crispatus CTV-05 produces lactic acid and hydrogen peroxide, adheres to vaginal epithelial cells, and antagonizes bacteria associated with BV and uropathogenic E. coli, which is responsible for most UTIs. LACTIN-V has also been shown to reduce preterm birth.

If you're in San Antonio this week attending the Tandem meetings, let's connect and discuss the latest breakthroughs in #celltherapy and how our new digital solution helps to improve patient access to advanced therapies! DM me at Christopher Leidli 🧬 #networking #advancedtherapies #genetherapies #pharma #biotech #venturecapital

From Missed Opportunity to Market Leader: The Weight-Loss Drug Race Heats Up! The weight-loss drug market is booming, and a fierce battle is brewing between pharma giants Eli Lilly and Company and Novo Nordisk. Decades ago, Lilly scientist Richard DiMarchi discovered a promising drug, but the company passed on it. Novo Nordisk seized the opportunity, developing GLP-1 drugs like Ozempic and Wegovy that dominate the market. Now, Lilly's back with Zepbound, a potentially even more effective contender. Both companies face challenges – competition, safety concerns, and sky-high valuations. Innovation is key in this fast-paced race, with the ultimate winner depending on who can deliver the best, safest, and most sustainable weight-loss solutions. So, who will win? And what are the implications for this growing market? Check the article link and share your thoughts! https://lnkd.in/grzGbxNv

Attending events like Life Science Strategy Summit on IP & Exclusivity in München gives NLO a chance to meet our IP colleagues in Pharma and dive into the latest developments in Life Science strategy in Pharma and to discuss and share knowledge on how to contribute to the success of drug development programs of our customers. That’s why Mari Korsten and Kolja Adamczyk join the Life Science Summit in Munchen on 8 - 10 Oct 2024. . . . #IP #IntellectualProperty #pharma #lifescience #strategy

New: Former Novartis CEO Joe Jimenez and the pharma's long-time research leader Mark Fishman are targeting $400 million for their third fund at Aditum Bio. The Oakland, CA-based firm in-licenses drugs, sets up a company around them and takes the experimental medicines through clinical development toward an M&A exit, like it has done with Versanis Bio, bought by Eli Lilly for up to $1.9 billion last year. Aditum has created 10 companies so far. “I was very clear with all of my investors that out of the 10 companies, I expect only three of them to provide good data, and seven of them will shut down,” Jimenez said in an interview with Endpoints News last fall. “Many times in pharma, if you’re in Phase 2 and you don’t get a positive readout, there’s a project team that’s willing to convince management that all they have to do is change the patient population, and they’re going to have success. That’s not what we’re about.” #biotech #vc #lifesciences #venturecapital #drugdevelopment